These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

145 related items for PubMed ID: 11369420

  • 1. Superiority of enoxaparin over heparin in combination with a GPIIb/IIIa receptor antagonist during coronary thrombolysis in dogs.
    Rebello SS, Kasiewski CJ, Bentley RG, Morgan SR, Chu V, Bostwick JS, Klein SI, Perrone MH, Leadley RJ.
    Thromb Res; 2001 May 01; 102(3):261-71. PubMed ID: 11369420
    [Abstract] [Full Text] [Related]

  • 2. Antithrombotic efficacy of a novel factor Xa inhibitor, FXV673, in a canine model of coronary artery thrombolysis.
    Rebello SS, Bentley RG, Morgan SR, Kasiewski CJ, Chu V, Perrone MH, Leadley RJ.
    Br J Pharmacol; 2001 Aug 01; 133(7):1190-8. PubMed ID: 11487531
    [Abstract] [Full Text] [Related]

  • 3. Comparison of enoxaparin, hirulog, and heparin as adjunctive antithrombotic therapy during thrombolysis with rtPA in the stenosed canine coronary artery.
    Leadley RJ, Kasiewski CJ, Bostwick JS, Bentley R, McVey MJ, White FJ, Perrone MH, Dunwiddie CT.
    Thromb Haemost; 1997 Oct 01; 78(4):1278-85. PubMed ID: 9364998
    [Abstract] [Full Text] [Related]

  • 4. Combination therapy with tirofiban and enoxaparin in acute coronary syndromes.
    Cohen M, Théroux P, Weber S, Laramée P, Huynh T, Borzak S, Diodati JG, Squire IB, Deckelbaum LI, Thornton AR, Harris KE, Sax FL, Lo MW, White HD.
    Int J Cardiol; 1999 Dec 01; 71(3):273-81. PubMed ID: 10636535
    [Abstract] [Full Text] [Related]

  • 5. Glycoprotein IIb/IIIa receptor antagonist (2S)-2-[(2-Naphthyl-sulfonyl)amino]-3-[[2-([4-(4-piperidinyl)-2-[2-(4-piperidinyl)ethyl] butanoyl]amino)acetyl]amino]propanoic acid dihydrochloride (CRL42796), in combination with aspirin and/or enoxaparin, prevents coronary artery rethrombosis after successful thrombolytic treatment by recombinant tissue plasminogen activator.
    Hong TT, Driscoll EM, White AJ, Sherigill A, Giboulot TA, Lucchesi BR.
    J Pharmacol Exp Ther; 2003 Aug 01; 306(2):616-23. PubMed ID: 12734394
    [Abstract] [Full Text] [Related]

  • 6. Initial experience with the low-molecular-weight heparin, enoxaparin, in combination with the platelet glycoprotein IIb/IIIa blocker, tirofiban, in patients with non-ST segment elevation acute coronary syndromes.
    Cohen M.
    J Invasive Cardiol; 2000 Dec 01; 12 Suppl E():E5-9;discussion E25-8. PubMed ID: 11156722
    [Abstract] [Full Text] [Related]

  • 7. Combining enoxaparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: final results of the National Investigators Collaborating on Enoxaparin-3 (NICE-3) study.
    Ferguson JJ, Antman EM, Bates ER, Cohen M, Every NR, Harrington RA, Pepine CJ, Theroux P, NICE-3 Investigators.
    Am Heart J; 2003 Oct 01; 146(4):628-34. PubMed ID: 14564315
    [Abstract] [Full Text] [Related]

  • 8. Administration of eptifibatide to acute coronary syndrome patients receiving enoxaparin or unfractionated heparin: effect on platelet function and thrombus formation.
    Lev EI, Hasdai D, Scapa E, Tobar A, Assali A, Lahav J, Battler A, Badimon JJ, Kornowski R.
    J Am Coll Cardiol; 2004 Mar 17; 43(6):966-71. PubMed ID: 15028351
    [Abstract] [Full Text] [Related]

  • 9. Increased reperfusion by glycoprotein IIb/IIIa receptor antagonist administration in case of unsuccessful and failed thrombolysis in patients with acute myocardial infarction: a pilot study.
    Di Pasquale P, Sarullo FM, Cannizzaro S, Vitrano MG, Giubilato A, Scalzo S, Giambanco F, Paterna S.
    Ital Heart J; 2001 Oct 17; 2(10):751-6. PubMed ID: 11721719
    [Abstract] [Full Text] [Related]

  • 10. Effects of heparin, aspirin and a synthetic platelet glycoprotein IIb-IIIa receptor antagonist (Ro 43-5054) on coronary artery reperfusion and reocclusion after thrombolysis with tissue-type plasminogen activator in the dog.
    Roux SP, Tschopp TB, Kuhn H, Steiner B, Hadváry P.
    J Pharmacol Exp Ther; 1993 Jan 17; 264(1):501-8. PubMed ID: 8423548
    [Abstract] [Full Text] [Related]

  • 11. The TETAMI trial: the safety and efficacy of subcutaneous enoxaparin versus intravenous unfractionated heparin and of tirofiban versus placebo in the treatment of acute myocardial infarction for patients not thrombolyzed: methods and design.
    Cohen M, Maritz F, Gensini GF, Danchin N, Timerman A, Huber K, Gurfinkel EP, White H, Fox KA, Vittori L, Le-Louer V, Bigonzi F.
    J Thromb Thrombolysis; 2000 Dec 17; 10(3):241-6. PubMed ID: 11122544
    [Abstract] [Full Text] [Related]

  • 12. Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial.
    Blazing MA, de Lemos JA, White HD, Fox KA, Verheugt FW, Ardissino D, DiBattiste PM, Palmisano J, Bilheimer DW, Snapinn SM, Ramsey KE, Gardner LH, Hasselblad V, Pfeffer MA, Lewis EF, Braunwald E, Califf RM, 'A to Z' Investigators.
    JAMA; 2004 Jul 07; 292(1):55-64. PubMed ID: 15238591
    [Abstract] [Full Text] [Related]

  • 13. Kistrin, a polypeptide platelet GPIIb/IIIa receptor antagonist, enhances and sustains coronary arterial thrombolysis with recombinant tissue-type plasminogen activator in a canine preparation.
    Yasuda T, Gold HK, Leinbach RC, Yaoita H, Fallon JT, Guerrero L, Napier MA, Bunting S, Collen D.
    Circulation; 1991 Mar 07; 83(3):1038-47. PubMed ID: 1900221
    [Abstract] [Full Text] [Related]

  • 14. Combination of a direct thrombin inhibitor and a platelet glycoprotein IIb/IIIa blocking peptide facilitates and maintains reperfusion of platelet-rich thrombus with alteplase.
    Sabatine MS, Tu TM, Jang IK.
    J Thromb Thrombolysis; 2000 Oct 07; 10(2):189-96. PubMed ID: 11005941
    [Abstract] [Full Text] [Related]

  • 15. Enoxaparin (Clexane, Lovenox), a low molecular weight heparin, enhances t-PA-induced coronary thrombus lysis in anesthetized dogs without inducing hypocoagulability.
    Mestre M, Uzan A, Sedivy P, Cavero I.
    Thromb Res; 1992 May 01; 66(2-3):191-206. PubMed ID: 1329253
    [Abstract] [Full Text] [Related]

  • 16. Preliminary experience with intravenous P2Y12 platelet receptor inhibition as an adjunct to reduced-dose alteplase during acute myocardial infarction: results of the Safety, Tolerability and Effect on Patency in Acute Myocardial Infarction (STEP-AMI) angiographic trial.
    Greenbaum AB, Ohman EM, Gibson CM, Borzak S, Stebbins AL, Lu M, Le May MR, Stankowski JE, Emanuelsson H, Weaver WD.
    Am Heart J; 2007 Oct 01; 154(4):702-9. PubMed ID: 17892995
    [Abstract] [Full Text] [Related]

  • 17. Intravenous administration of the glycoprotein IIb-IIIa receptor antagonist 7E3 induces reperfusion of an acute thrombotic occlusion of the canine coronary artery.
    Shetler TJ, Bailey BD, Jakubowski JA, Jackson CV.
    Thromb Res; 1998 Apr 15; 90(2):95-100. PubMed ID: 9684763
    [Abstract] [Full Text] [Related]

  • 18. The safety and efficacy of subcutaneous enoxaparin versus intravenous unfractionated heparin and tirofiban versus placebo in the treatment of acute ST-segment elevation myocardial infarction patients ineligible for reperfusion (TETAMI): a randomized trial.
    Cohen M, Gensini GF, Maritz F, Gurfinkel EP, Huber K, Timerman A, Krzeminska-Pakula M, Danchin N, White HD, Santopinto J, Bigonzi F, Hecquet C, Vittori L, TETAMI Investigators.
    J Am Coll Cardiol; 2003 Oct 15; 42(8):1348-56. PubMed ID: 14563573
    [Abstract] [Full Text] [Related]

  • 19. Eptifibatide and low-dose tissue plasminogen activator in acute myocardial infarction: the integrilin and low-dose thrombolysis in acute myocardial infarction (INTRO AMI) trial.
    Brener SJ, Zeymer U, Adgey AA, Vrobel TR, Ellis SG, Neuhaus KL, Juran N, Ivanc TB, Ohman EM, Strony J, Kitt M, Topol EJ.
    J Am Coll Cardiol; 2002 Feb 06; 39(3):377-86. PubMed ID: 11823073
    [Abstract] [Full Text] [Related]

  • 20. Intracoronary thrombus and platelet glycoprotein IIb/IIIa receptor blockade with tirofiban in unstable angina or non-Q-wave myocardial infarction. Angiographic results from the PRISM-PLUS trial (Platelet receptor inhibition for ischemic syndrome management in patients limited by unstable signs and symptoms). PRISM-PLUS Investigators.
    Zhao XQ, Théroux P, Snapinn SM, Sax FL.
    Circulation; 1999 Oct 12; 100(15):1609-15. PubMed ID: 10517731
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.